JNJ / AbelZeta and Mustang Bio Present Clinical Updates from their Assets Targeting CD20 in NHL; ASH 2023 Analysis 5
Here is a brief preview of this blast: ASH 2023 Analysis 5: JNJ / AbelZeta and Mustang Bio presented clinical updates from assets targeting CD20 in NHL. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below: